The Friday Five – World Alzheimer’s Month
September is World Alzheimer’s Month, an international campaign to raise dementia awareness and challenge stigma. Each year, Alzheimer associations from around the world unite to organize advocacy and information provision events, as well as Memory Walks and fundraising days. This week’s Friday Five shares updates about the disease, the latest in research, funding and what the future holds.
The Brain Trust
A Physician’s practical guide to Alzheimer’s and Related Dementias
Welcome to The Brain Trust, a podcast for and by physicians designed to help improve screening, diagnosis, and treatment of Alzheimer’s disease and related dementias in clinical workflows. Tune in weekly to hear our guest primary care clinicians discuss innovative ways to support patients and their families in better managing brain disease.
Follow the podcast at #TheBrainTrustPod
Alzheimer’s Disease International: World Alzheimer’s Month
World Alzheimer’s Month is the international campaign by Alzheimer’s Disease International every September to raise awareness and challenge the stigma that surrounds dementia. World Alzheimer’s Month was launched in 2012. World Alzheimer’s Day is on 21 September each year. ADI (@AlzDisInt) is the global voice on dementia. They raise awareness by supporting Alzheimer associations and individuals worldwide. The World Alzheimer’s Month 2023 campaign, ‘Never too early, never too late‘, will centre around risk factors and risk reduction.
Our new From Plan to Impact VI report is now available.
— ADI (@AlzDisInt) May 24, 2023
The Ahead Study is Testing Lecanemab at the Stage of Preclinical Alzheimer’s Disease
‘Alzheimer’s disease (AD) researchers increasingly believe that treating at the earliest possible stage may be key to helping combat the disease. Ongoing studies are now testing whether lecanemab can effectively delay or prevent the symptoms of disease if started even before there is evidence of cognitive impairment.
The AHEAD Study is testing the effect of lecanemab in people who have no cognitive symptoms of AD but in whom biomarker tests indicate amyloid is present in the brain, known as the “preclinical” stage of AD. The AHEAD Study is the first AD trial to recruit people as young as 55 years old who are at risk of developing symptoms of AD as they get older.” Full press release here.
“Linus Health, (@linushealth) a digital health company focused on early detection of Alzheimer’s and other dementias, announced that company leaders and collaborators are presenting results from eight new studies involving its digital cognitive assessment solutions at the 2023 Alzheimer’s Association International Conference. The results not only further validate Linus’ AI-enhanced technology’s ability to outperform paper-based cognitive tests in detecting mild cognitive impairment (MCI) and dementia and help identify underlying causes, but also demonstrate its transferability from research to clinical practice.” Full press release here.
Alzheimer’s Association International Conference | In-Person, Philadelphia or Virtual
Date: July 28 – August 1, 2024
Description: Join distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest international conference on dementia science. Share theories and breakthroughs while exploring opportunities to accelerate your work and elevate your career.
Register: March 2024 – here
Follow: #AAIC23, @alzassociation
Alzheimer’s Association Announces New Dementia Care Navigation Roundtable
“The Alzheimer’s Association announced it is launching the Dementia Care Navigation Roundtable (DCNR) to drive access and support for people newly diagnosed and living with dementia. The recent advancements of new Alzheimer’s treatments are expected to result in more people seeking care and services. The DCNR will support broad implementation of dementia care navigation by convening experts, sharing best practices, and disseminating resources. The DCNR will include experts from across the healthcare industry, including systems, clinicians, payers, researchers, and other stakeholders who are committed to advancing the delivery of high-quality, person-centered dementia care navigation.” Full press release here.
A paper published online in the Alzheimer’s Association open-access journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions (TRCI) will provide a foundation for the Dementia Care Navigation Roundtable’s work. https://t.co/j0FsRD7pYd
— Alzheimer’s Association (@alzassociation) August 2, 2023